Answers are grounded in this paper and cite their sources.
Randomized trial evaluates Merocel's effectiveness in preventing pressure injuries in ICU patients, suggesting a practical intervention.
Background: Nasogastric tubes (NGTs) are necessary for severely ill patients, especially in intensive care units. However, they are frequently associated with pressure injuries to the nose. This trial, conducted at Helwan University Hospitals, evaluates the protective role of Merocel as a barrier against NGT-associated pressure injuries (NTAPIs). Methods: A prospective, controlled clinical study was conducted over a six-month period at Helwan University Hospitals. Seventy-eight adult ICU patients requiring NGTs were randomized into two groups: one receiving Merocel intranasal packing (n = 39) and one receiving standard care without Merocel (n = 39). Merocel dressings were cut, lubricated with Neosporin™, and replaced every 48–72 hours. Patients were assessed every 48 hours. The primary outcome was the integrity of the ala nasi. Results: NTAPIs occurred in five patients (12.82%) in the control group, but none in the Merocel group, demonstrating a significant reduction (p = 0.027). The NGT duration did not differ significantly between groups. A slightly higher rate of discomfort was reported in the study group versus the control group (12.82% vs. 0%, p = 0.027). No other adverse events were reported in the study group, further supporting the success of the Merocel group. Conclusion: Using Merocel reduces the incidence of pressure injuries associated with NGT. However, its use requires proper training for safe insertion, thorough lubrication, and scheduled replacement every 48–72 hours.
No takes yet. Share an insight, caveat, or question.
Hamed et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: